公开(公告)号：HU0202424A2

公开(公告)日：2002-11-28

申请号：HU0202424

申请日：2000-07-10

Applicant: SOLVAY PHARM GMBH

Inventor： PAPP JULIUS GY ,  ROZSA ZSUZSANNA ,  THORMAEHLEN DIRK ,  WALDECK HARALD

IPC: A61K31/55 ,  C07D223/16 ,  A61K31/704 ,  A61K45/00 ,  A61K45/06 ,  A61P9/00 ,  A61P21/00 ,  A61P35/00 ,  A61P37/04 ,  A61P39/02 ,  A61P39/06

Abstract: The use of benzazepin-N-acetic acid derivatives which contain an oxo group in the a position to the nitrogen atom and are substituted in the 3 position by a 1-(carboxyalkyl)-cyclopentyl-carbonyl-amino radical, and of their salts and biolabile esters, for the prophylaxis and/or treatment of heart damage caused by cardiotoxic doses of medicaments or chemicals, in larger mammals and in particular humans. The invention is particularly applicable to the prophylaxis and/or treatment of heart damage, in particular to the myocardium, which may occur during cytostatic chemotherapy. The invention also includes the use of the afore-mentioned benzazepin-N-acetic acid derivatives for adjuvant treatment in therapies in which medicaments having oxidative-toxic side-effects are used, and the preparation of medicaments suitable for this prophylaxis and/or treatment or adjuvant treatment.

公开(公告)号：BR0012442A

公开(公告)日：2002-04-02

申请号：BR0012442

申请日：2000-07-10

Applicant: SOLVAY PHARM GMBH

Inventor： ROZSA ZSUZSANNA ,  PAPP JULIUS GY ,  THORMAEHLEN DIRK ,  WALDECK HARALD

IPC: C07D223/16 ,  A61K31/55 ,  A61K31/704 ,  A61K45/00 ,  A61K45/06 ,  A61P9/00 ,  A61P21/00 ,  A61P35/00 ,  A61P37/04 ,  A61P39/02 ,  A61P39/06 ,  A61K31/70

Abstract: The use of benzazepin-N-acetic acid derivatives which contain an oxo group in the a position to the nitrogen atom and are substituted in the 3 position by a 1-(carboxyalkyl)-cyclopentyl-carbonyl-amino radical, and of their salts and biolabile esters, for the prophylaxis and/or treatment of heart damage caused by cardiotoxic doses of medicaments or chemicals, in larger mammals and in particular humans. The invention is particularly applicable to the prophylaxis and/or treatment of heart damage, in particular to the myocardium, which may occur during cytostatic chemotherapy. The invention also includes the use of the afore-mentioned benzazepin-N-acetic acid derivatives for adjuvant treatment in therapies in which medicaments having oxidative-toxic side-effects are used, and the preparation of medicaments suitable for this prophylaxis and/or treatment or adjuvant treatment.

公开(公告)号：AT197801T

公开(公告)日：2000-12-15

申请号：AT96104265

申请日：1996-03-18

Applicant: SOLVAY PHARM GMBH

Inventor： WALDECK HARALD ,  HOELTJE DAGMAR ,  MESSINGER JOSEF ,  ANTEL JOCHEN ,  WURL MICHAEL ,  THORMAEHLEN DIRK

IPC: C07D223/16 ,  A61K31/33 ,  A61K31/423 ,  A61K31/428 ,  A61K31/55 ,  A61K31/554 ,  A61K38/00 ,  A61K38/05 ,  A61P7/10 ,  A61P9/00 ,  A61P43/00 ,  C07D267/14 ,  C07D281/10 ,  C07K5/078

Abstract: Benzazepin-, benzoxazepin- and benzothiazepin-N-acetic acid derivs. of formula (I) and their salts are new. R = lower alkoxy(lower)alkyl (in which the alkoxy is opt. substd. by lower alkoxy) or phenyl(lower)alkyl, or phenoxy(lower)alkyl (opt. ring substd. by lower alkyl or alkoxy or halo) or naphthyl(lower)alkyl; A = CH2, O or S; R , R = H or halogen; R , R = H or a biolabile ester containing gp.

公开(公告)号：CA2253997A1

公开(公告)日：1999-05-12

申请号：CA2253997

申请日：1998-11-12

Applicant: SOLVAY PHARM GMBH

Inventor： WURL MICHAEL ,  THORMAEHLEN DIRK ,  MEIL JOERG ,  WALDECK HARALD

IPC: A61K31/675 ,  A61K31/00 ,  A61K31/55 ,  A61K38/00 ,  A61K38/05 ,  A61P9/00 ,  A61P9/04 ,  A61P9/12 ,  C07D223/16 ,  C07F9/38 ,  C07F9/40 ,  C07F9/553 ,  C07K5/06 ,  C07F9/6558

Abstract: Compounds having NEP-inhibitory activity, corresponding to the formula I in which R1 is hydrogen or a group forming a biolabile phosphonic acid ester, R2 is hydrogen or a group forming a biolabile phosphonic acid ester and R3 is hydrogen or a group forming a biolabile carboxylic acid ester and physiologically acceptable salts of acids of formula I, and pharmaceutical compositions comprising these compounds.

公开(公告)号：HU9701540D0

公开(公告)日：1997-10-28

申请号：HU9701540

申请日：1997-09-15

Applicant: SOLVAY PHARM GMBH

Inventor： PAPP JULIUS ,  ROZSA SUSANNA ,  THORMAEHLEN DIRK ,  WALDECK HARALD

IPC: C07D223/16 ,  A61K31/55 ,  A61P1/00

公开(公告)号：AU2004290925B2

公开(公告)日：2010-07-01

申请号：AU2004290925

申请日：2004-11-15

Applicant: SOLVAY PHARM GMBH

Inventor： WALDECK HARALD ,  THORMAEHLEN DIRK ,  HOCHER BERTHOLD

IPC: A61K31/55

公开(公告)号：DE602004012763T2

公开(公告)日：2009-05-07

申请号：DE602004012763

申请日：2004-10-07

Applicant: SOLVAY PHARM GMBH

Inventor： BAUM DOMINIQUE ,  BIELENBERG GERHARD-WILHELM ,  BOEDECKER BERND ,  THORMAEHLEN DIRK

IPC: A61K45/06 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/506 ,  A61P9/14

Abstract: Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.

公开(公告)号：DE602004010172T2

公开(公告)日：2008-09-11

申请号：DE602004010172

申请日：2004-11-15

Applicant: SOLVAY PHARM GMBH

Inventor： THORMAEHLEN DIRK ,  HOCHER BERTHOLD ,  WALDECK HARALD

IPC: A61K31/55 ,  A61P13/12 ,  A61P43/00

公开(公告)号：DE602004012763D1

公开(公告)日：2008-05-08

申请号：DE602004012763

申请日：2004-10-07

Applicant: SOLVAY PHARM GMBH

Inventor： BAUM DOMINIQUE ,  BIELENBERG GERHARD-WILHELM ,  BOEDECKER BERND ,  THORMAEHLEN DIRK

IPC: A61K45/06 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/506 ,  A61P9/14

Abstract: Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.

公开(公告)号：ES2297536T3

公开(公告)日：2008-05-01

申请号：ES04818828

申请日：2004-11-15

Applicant: SOLVAY PHARM GMBH

Inventor： THORMAEHLEN DIRK ,  HOCHER BERTHOLD ,  WALDECK HARALD

IPC: A61K31/55 ,  A61P13/12 ,  A61P43/00

Abstract: Uso de un compuesto de fórmula general I: en el que R1 significa un grupo fenil-alquilo C1-4 que puede estar sustituido opcionalmente en el anillo de fenilo por alquilo C1-4, alcoxi C1-4 o halógeno, o por un grupo naftil-alquilo C1-4, R2 significa hidrógeno o un grupo que forma un éster biolábil, y R3 significa hidrógeno o un grupo que forma un grupo biolábil, en el que un grupo que forma un éster biolábil se selecciona independientemente en cada caso de un grupo alquilo C1-C4; un grupo fenilo o fenil-alquilo C1-C4, particularmente fenilo, bencilo o indanilo, que opcionalmente está sustituido en el anillo fenilo por alquilo C1-C4 o por una cadena de alquileno C1-C4 unida a dos átomos de carbono adyacentes, o un grupo dioxolanilmetilo, particularmente (2, 2-dimetil-1, 3-dioxolan-4-il)metilo, que opcionalmente está sustituido en el anillo de dioxolano por alquilo C1-C4, o un grupo alcano C2-C6-iloximetilo opcionalmente sustituido en el grupo oximetilo por alquilo C1-C4; y/o de una sal fisiológicamente aceptable de los ácidos de fórmula I, y/o su solvato fisiológicamente aceptable para la fabricación de una composición farmacéutica para el tratamiento y/o la profilaxis de nefropatía que comprende la excreción de proteinuria, albúmina urinaria y/o cicatrización renal en un paciente humano.